GGrantIndex
Sort

82,697 grants matching vaccine development

Integrated Services Core

$895,766
William Paul Duprex · University Of Pittsburgh At Pittsburgh · UC7 · FY2025 · AI

HANTAVIRUS ECOLOGY AND DISEASE IN CHILE AND PANAMA

$895,759
University Of New Mexico · U19 · FY2005 · AI

Non-Human Primate Core

$895,730
Mario Roederer · National Institute Of Allergy And Infectious Diseases · ZIC · FY2016 · AI

Development of Novel Therapeutic Agents for Norovirus Infection

$895,635
Kyeong-Ok Chang · Kansas State University · U01 · FY2013 · AI

Malaria Parasite Ligands And Host Cell Receptors

$895,579
Louis Miller · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI

A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease

$895,539
Gary Fanger · Rise Therapeutics, Llc · R44 · FY2021 · DK

NLM's Personal Health Record and Consumer Service R&D

$895,449
Clement McDonald · National Library Of Medicine · ZIA · FY2013 · LM

In vivo CRISPR engineering of B cells to produce anti-HIV broadly neutralizing antibodies using novel nanoparticles

$895,395
Jennifer Eileen Adair · Fred Hutchinson Cancer Center · R01 · FY2024 · AI

Entry and replication of positive-sense, RNA viruses

$895,330
Joseph Marcotrigiano · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI

Core 2: BSL-3 Practices Core

$895,157
Scott Alderman · Duke University · UC7 · FY2024 · AI

Targeting bacterial cell wall biogenesis for the development of novel antimicrob

$895,104
Thomas G Bernhardt · Harvard Medical School · U19 · FY2016 · AI

Development of PSMA -based recombinant protein vaccines

$895,094
Gerald P Donovan · Progenics Pharmaceuticals, Inc. · R44 · FY2007 · CA

Partnership for Detection of Infection by Category B Pathogens

$895,035
Frances S. Ligler · U.S. Naval Research Laboratory · U01 · FY2008 · AI

Development of IMPDH-Targeted Drugs against Crytosporidium

$895,013
Lizbeth K. Hedstrom · Brandeis University · U01 · FY2009 · AI

Protease-resistant D-peptide Inhibitors of Ebola Virus Entry

$894,941
Brett D Welch · Navigen, Inc. · R44 · FY2017 · AI

Frameshift peptide vaccine for the prevention Lynch syndrome-associated gastrointestinal cancer HHSN2612015000391 TORFP: 2018-E12 POP: 9/17/2018 to 3/16/2021

$894,832
Steven Monroe Lipkin · Weill Medical Coll Of Cornell Univ · N01 · FY2018 · CA

Antibody Based Therapeuticcs for Chikungunya Virus

$894,815
Michael S. Diamond · Washington University · R01 · FY2013 · AI

A novel strategy for vaccine-induced protection against maternal-to-fetal transmission of Zika virus

$894,640
Sujan Shresta · La Jolla Institute For Immunology · R01 · FY2024 · AI

CAREER: Deciphering the nanoparticle-lymphatic vessel interface for modulating immunity

$894,572
Katharina Maisel · University Of Maryland, College Park · · FY2021 · MPS

SEQUENCE AND POLYMORPHISM OF RHESUS MACAQUE MHC

$894,547
Fred Hutchinson Cancer Research Center · R24 · FY2004 · RR

Development of the Next Generation of Conjugate Vaccines

$894,543
Luc Teyton · Scripps Research Institute, The · R01 · FY2018 · AI

Identification of the Initial Targets of Transmission

$894,537
Thomas Hope · Northwestern University At Chicago · R37 · FY2023 · AI

ESTABLISHMENT/MAINTENANCE OF BIOMEDICAL RESEARCH COLONY

$894,422
University Of Louisiana At Lafayette · U42 · FY2004 · RR

Increasing the size of the specific pathogen free Indian rhesus macaques colony at the Southwest National Primate Research Center for AIDS, COVID-19 and other infectious diseases research

$894,342
Larry S. Schlesinger · Texas Biomedical Research Institute · P51 · FY2021 · OD

INNATE IMMUNE RESPPONSE TO MICROBIAL INFECTION

$894,121
University Of Iowa · P01 · FY2001 · AI